Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, November 16, 2018 · 468,534,318 Articles · 3+ Million Readers

Organ-on-Chips Industry Awaits Regulatory Approval, New Report Explains

LONDON, GREATER LONDON, UK, September 19, 2018 /EINPresswire.com/ -- Organs-on-chips (OOCs) are a revolutionary new technology for drug development but their full potential will only be realized when regulatory approval is given for using the data generated from OOCs in the pharmaceutical industry's regulatory submissions, The Business Research Company's report Organ-On-Chip Global Market Opportunities And Strategies To 2021 explains.

Organs-on-chips are microfluidic 3D cell culture devices that closely mimic the key physiological functions of body organs. Most chips are not designed to biomimic an entire organ, but simulate the physiology of a single functional unit of an organ system. They have resulted from scientific advances in cell biology, microfabrication and microfluidics which allow the emulation of the human micro environment in vitro. This unique feature of OOCs is made possible by integrating biology with advanced engineering technologies. Human organs-on-chips (OOCs) are miniaturized versions of lungs, livers, kidneys, heart, brain, intestines and other vital human organs embedded in a chip.

Download a sample of the report at https://www.thebusinessresearchcompany.com/sample.aspx?id=805&type=smp

OOC technology offers a less time-consuming and more cost-effective way to test for the efficacy and toxicity of new drugs, foods, cosmetics and dietary supplements. Overall, they have the potential to break an impasse in in-vitro discovery and development in these fields. However, at present, owing to the neoteric nature of OOC technology no regulations exist for the use of OOCs in drug testing and OOC-based evidence is not accepted in drug approval processes. In the long run, however, OOC companies are expected to get approval from regulatory bodies such as the US FDA and Europe’s EMA for their products. This will help pharmaceutical companies to use the data generated from OOCs in their research and regulatory submissions.

The Business Research Company (TBRC) is optimistic about the prospects for this technology, because, as a senior sales and marketing manager from Novartis put it, “The value proposition of OOCs for pharmaceutical companies is very strong in terms of reducing clinical failure rates and reliance on animal testing”. TBRC's forecast is for the market's growth rate to accelerate.

Organ-on-Chips Global Market Opportunities And Strategies To 2022 is one of a series of new industry reports from The Business Research Company that identify opportunities and explain strategies in a range of industries, provide a market overview, analysis and forecasts of market size and industry statistics, market growth rates, market trends, market drivers, market restraints, market revenues, market shares and company profiles of the leading competitors in over 300 industry reports, covering over 2400 market segments and 60 geographies. The industry reports draw on 150,000 datasets. Extensive secondary research is augmented with exclusive insights and quotations from industry leaders obtained through interviews. Market analysis and forecasts are provided by a highly experienced and expert team of analysts and modellers.

Request for Discount at https://www.thebusinessresearchcompany.com/sample.aspx?id=805&type=discount

Where to Learn More
Read Organ-on-Chip (OOC) Global Market Opportunities and Strategies To 2022 from The Business Research Company for information on the following:

Markets Covered: organ-on-chip industry, lung-on-chip industry, heart-on-chip industry, liver-on-chip industry, intestine-on-chip industry, kidney-on-chip industry, human-on-chip industry, human disease and tissue models, and microfluidics
Companies Mentioned: CN Bio Innovations, Emulate Inc., TissUse GmbH, Mimetas, HµREL Corporation (HµREL), Nortis, InSphero, Tara Biosystems, and AxoSim Techologies LLC
Regions: North America, Europe, Asia and Rest Of World (ROW)
Time series: Historic and Forecast 2011 to 2021
Data: Market value in $ Million
Number of Figures: 66
Number of Tables: 78
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes.

Download Complete Table of Contents at https://www.thebusinessresearchcompany.com/sample.aspx?id=805&type=toc

Interested To Know More? Here is a list of reports from The Business Research Company similar to Organ-On-Chip Global Market Opportunities And Strategies To 2021
Biologics Global Market Opportunities And Strategies To 2021
Blood Glucose Test Strips Global Market Opportunities And Strategies To 2021 (https://www.thebusinessresearchcompany.com/report/blood-glucose-test-strips-global-market-opportunities-and-strategies-to-2021)
Healthcare Services Global Market Report 2018 (https://www.thebusinessresearchcompany.com/report/healthcare-services-global-market-report-2018 )

About The Business Research Company
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company’s management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations. The Business Research Company’s Consultants have master’s qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company’s Consultants gain training and qualifications from the Market Research Society and are trained in advanced research practices, techniques, and ethics.

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here

Powered by EIN Presswire